SLCO1B1 and Patent ductus arteriosus: Therefore, although ritlecitinib exceeded the regulatory OAT1/3 and OATP1B1 drug interaction risk cutoffs, it was anticipated that ritlecitinib would have a minimal impact on the AUC of both PDA and CP-I.